A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
Status:
Completed
Trial end date:
2016-08-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of ASP8232 in subjects with
diabetic macular edema (DME). This study will evaluate the percent change from baseline in
excess central subfield thickness (CST) in the study eye as assessed by spectral
domain-optical coherence Tomography (SD-OCT) for ASP8232 monotherapy at Month 3.